Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Besifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.86 |
| ▸ | POLB | P06746 | 2/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.86 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 7/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Besifloxacin SCHEMBL28011379 | 1.00 | ALDH1A1 (0.86) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL29359545 | 1.00 | ALDH1A1 (0.86) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL725805 | 0.99 | ALDH1A1 (0.88) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL5959095 | 0.99 | ALDH1A1 (0.88) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Besifloxacin SCHEMBL725804 | 0.99 | ALDH1A1 (0.88) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL5571098 | 0.94 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL193233 | 0.94 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL193234 | 0.94 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL29682535 | 0.94 | ALDH1A1 (0.98) | ALDH1A1POLBOPRM1CHRM2CHRM1 | |
| Clinafloxacin SCHEMBL33959 | 0.93 | ALDH1A1 (1.00) | ALDH1A1POLBOPRM1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246814-A | Synthetic method of fluoroquinolone antibacterial drugs | 江苏开元药业有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2020-05-07 | — | — | US | disclosed |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | VYOME THERAPEUTICS LIMITED (IN) | 2020-02-25 | — | — | US | disclosed |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME THERAPEUTICS LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| EP-3328856-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | Vyome Biosciences Pvt. Ltd. (IN) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017631-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2017-02-02 | — | — | WO | disclosed |
| CN-104592196-A | Preparation method of besifloxacin hydrochloride | GUANGXI RENHENG PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| US-20130345259-A9 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines | BAUSCH HEALTH HOLDCO LIMITED (IE) | 2013-12-26 | — | — | US | disclosed |
| US-20130289070-A1 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines | BAUSCH & LOMB (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013126156-A1 | NITRIC OXIDE DONATING SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST COMPOUNDS AND OPHTHALMIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2013-08-29 | — | — | WO | disclosed |
| EP-2049112-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | Bausch & Lomb Incorporated (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009023471-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090042936-A1 | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation | ORAPHARMA, INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2009006141-A2 | AUTHORITY TO READ AS FOLLOWS: COMPOSITIONS AND METHODS FOR TREATING OR CONTROLLING INFECTIONS OF THE EYE A SEQUELAE THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008033655-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB INCORPORATED (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | BAUSCH & LOMB INCORPORATED | 2008-03-13 | — | — | US | disclosed |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | VRX HOLDCO LLC | 2008-03-06 | — | — | US | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008021728-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED' GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | ALDH1A1 3717/4885POLB 1632/4885OPRM1 1553/4885 |
| US-20090042936-A1 | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation | NR3C1, GCGR, GNRHR | ALDH1A1 3800/4885POLB 2565/4885OPRM1 2482/4885 |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | ALDH1A1 4010/4885POLB 520/4885OPRM1 1857/4885 |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | PTGIR, PTGDR, NR3C1 | ALDH1A1 2473/4885POLB 2294/4885OPRM1 1770/4885 |
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | ALDH1A1 4010/4885POLB 520/4885OPRM1 1857/4885 |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | CLPP, CFTR, ELANE | ALDH1A1 4010/4885POLB 520/4885OPRM1 1857/4885 |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | ALDH1A1 2165/4885POLB 3503/4885OPRM1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.